These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37671923)

  • 1. Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice.
    Rieg T; Xue J; Stevens M; Thomas L; White JR; Dominguez Rieg JA
    Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37671923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
    Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
    J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.
    Pollock RF; Kalra PA; Kalra PR; Ahmed FZ
    Adv Ther; 2022 Oct; 39(10):4678-4691. PubMed ID: 35947351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland.
    Pollock RF; Muduma G
    Clinicoecon Outcomes Res; 2021; 13():9-18. PubMed ID: 33442276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose.
    Hu S; Liu L; Pollock RF; Pöhlmann J; Wu D; Zhang Y
    J Med Econ; 2022; 25(1):561-570. PubMed ID: 35403540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Hypophosphatemia After Intravenous Administration of Iron: A Matching-Adjusted Indirect Comparison of Data from Japanese Randomized Controlled Trials.
    Fukumoto S; Murata T; Osuga Y; Pollock RF
    Adv Ther; 2023 Nov; 40(11):4877-4888. PubMed ID: 37702931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic literature review and meta-analysis of the incidence of serious or severe hypersensitivity reactions after administration of ferric derisomaltose or ferric carboxymaltose.
    Kennedy NA; Achebe MM; Biggar P; Pöhlmann J; Pollock RF
    Int J Clin Pharm; 2023 Jun; 45(3):604-612. PubMed ID: 37010731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy, Safety, and Economic Outcomes of Using Ferric Derisomaltose for the Management of Iron Deficiency in China: A Rapid Health Technology Assessment.
    Yun L; YuMei Z; Bn V; Tang Q; Feng C
    Cureus; 2023 Nov; 15(11):e48717. PubMed ID: 38094535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia.
    Pollock RF; Biggar P
    Expert Rev Hematol; 2020 Feb; 13(2):187-195. PubMed ID: 31928094
    [No Abstract]   [Full Text] [Related]  

  • 12. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients.
    Liu H; Wu W; Luo Y
    Int Urol Nephrol; 2023 Mar; 55(3):759-767. PubMed ID: 36166104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 15. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.
    Boots JMM; Quax RAM
    Drug Saf; 2022 Oct; 45(10):1019-1036. PubMed ID: 36068430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron.
    Lichtenstein GR; Onken JE
    Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hemoglobin extracted from
    Sun B; Tan B; Zhang P; Huang T; Wei H; Li C; Yang W
    Food Funct; 2023 Jul; 14(15):7040-7052. PubMed ID: 37449470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.